Neurologist. Head of Hospitalizations

  • Mentor of residents
  • Area director of Revista de Neurología
  • Chair of the Teaching Commission, Vall d’Hebron University Hospital


Medicine and Surgery
Phd in Medicine


Associate doctor and researcher at Neurology/Neuroimmunology Department, Vall d’Hebron University Hospital. Dr. Río trained as a neurologist at Vall d’Hebron University Hospital and he received his Phd in Medicine at Universitat Autònoma de Barcelona.

He has authored more than 100 original articles and reviews in international journals, as well as many book chapters. Over the past 20 years, Dr. Río has been involved in the development of important clinical trials about Multiple Sclerosis. He has participated in the first Spanish (second worldwide) Multiple Sclerosis Clinical Practice Guidelines.

Projects / Lines of Research / Interests

Dr. Río’s work is primarily based on the prospective study of patients with Multiple Sclerosis treated with immunomodulators. Last years he has studied some factors related to this treatment as the search of clinical, radiological and biological markers.

The implications of his work have been of significant impact both in clinical practice to allow the identification of patients at risk -who in principle are tributaries of more aggressive treatments- and when it comes to the design of clinical trials primary objectives since criteria proposed by Dr. Río are currently in use.

Nowadays his research activity is focused on the search of clinical, radiological and genetic markers of response to immunomodulatory drugs.


1: Río J, Ruiz-Peña JL. Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis. J Neurol Sci. 2016 Feb 15;361:158-67. doi: 10.1016/j.jns.2015.12.043. Epub 2015 Dec 29

2: Río J: Any evident MRI T2 lesion activity should guide change of therapy in multiple sclerosis: no. Mult Scler. 2015 Feb;21(2):132-3. 

3: Vidal-Jordana A, Sastre-Garriga J, Pérez-Miralles F, Pareto D, Río J, Auger C, Tintoré M, Rovira A, Montalban X. Brain Volume Loss during the First Year of Interferon-Beta Treatment: Baseline Inflammation and Tissue-Specific Volume Dynamics. J Neuroimaging. 2016 Mar 2. doi: 10.1111/jon.12337. [Epub ahead of print] PubMed PMID: 26935253.

4: Comabella M, Cantó E, Nurtdinov R, Río J, Villar LM, Picón C, Castilló J, Fissolo N, Aymerich X, Auger C, Rovira A, Montalban X. MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes. Hum Mol Genet. 2016 Jan 15;25(2):308-16. doi: 10.1093/hmg/ddv473. Epub 2015 Nov 24. PubMed PMID: 26604134.

5: Bustamante MF, Morcillo-Suárez C, Malhotra S, Río J, Leyva L, Fernández O, Zettl UK, Killestein J, Brassat D, García-Merino JA, Sánchez AJ, Urcelay E, Alvarez-Lafuente R, Villar LM, Alvarez-Cermeño JC, Farré X, Lechner-Scott J, Vandenbroeck K, Rodríguez-Antigüedad A, Drulovic JS, Martinelli Boneschi F, Chan A, Oksenberg J, Navarro A, Montalban X, Comabella M. Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN-β. Neurol Neuroimmunol Neuroinflamm. 2015 Sep 24;2(5):e154. doi: 10.1212/NXI.0000000000000154. eCollection 2015 Oct. PubMed PMID: 26445728; PubMed Central PMCID: PMC4582905.

6: Kuhle J, Hardmeier M, Disanto G, Gugleta K, Ecsedi M, Lienert C, Amato MP, Baum K, Buttmann M, Bayas A, Brassat D, Brochet B, Confavreux C, Edan G, Färkkilä M, Fredrikson S, Frontoni M, D'Hooghe M, Hutchinson M, De Keyser J, Kieseier BC, Kümpfel T, Río J, Polman C, Roullet E, Stolz C, Vass K, Wandinger KP, Kappos L; European Long-term Follow-up Study Group in Interferon β-1b in Secondary-progressive Multiple Sclerosis. A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis. Mult Scler. 2016 Apr;22(4):533-43. doi: 10.1177/1352458515594440. Epub 2015 Sep 11. PubMed PMID: 26362898.

7: Pérez-Miralles FC, Sastre-Garriga J, Vidal-Jordana A, Río J, Auger C, Pareto D, Tintoré M, Rovira A, Montalban X. Predictive value of early brain atrophy on response in patients treated with interferon β. Neurol Neuroimmunol Neuroinflamm. 2015 Jul 2;2(4):e132. doi: 10.1212/NXI.0000000000000132. eCollection 2015 Aug. PubMed PMID: 26185778; PubMed Central PMCID: PMC4496631.

9: Tintore M, Rovira À, Río J, Otero-Romero S, Arrambide G, Tur C, Comabella M, Nos C, Arévalo MJ, Negrotto L, Galán I, Vidal-Jordana A, Castilló J, Palavra F, Simon E, Mitjana R, Auger C, Sastre-Garriga J, Montalban X. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain. 2015 Jul;138(Pt 7):1863-74. doi: 10.1093/brain/awv105. Epub 2015 Apr 21. PubMed PMID: 25902415.

9: Multiple sclerosis: current treatment algorithms.Río J, Comabella M, Montalban X. Curr Opin Neurol. 2011 Jun;24(3):230-7

10: Predicting responders to therapies for multiple sclerosis. Río J, Comabella M, Montalban X. Nat Rev Neurol. 2009

11: Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Río J, Nos C, Tintoré M, Téllez N, Galán I, Pelayo R, Comabella M, Montalban X. Ann Neurol. 2006 Feb;59(2):344-52.

12: Measures in the first year of therapy predict the response to interferon beta in MS. Río J, Castilló J, Rovira A, Tintoré M, Sastre-Garriga J, Horga A, Nos C, Comabella M, Aymerich X, Montalbán X. Mult Scler. 2009 Jul;15(7):848-53.